Chemogene therapy

Osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a marine osteosarcoma model

Jun Cheon, Song Chu Ko, Thomas Gardner, Toshiro Shirakawa, Akinobu Gotoh, Chinghai Kao, Leland W K Chung

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

We previously reported that the recombinant adenovirus (Ad) vector containing the thymidine kinase (TK) gene driven by the osteocalcin (OC) promoter (Ad-OC-TK), when delivered concurrently with acyclovir (ACV), is highly selective in blocking the growth of osteosarcoma in experimental models (Cancer Res. 1996;56:4614-4619). To investigate the possible additive effects of the combined treatment of gene therapy and conventional chemotherapy (chemogene therapy), we compared the effect of low dose (IC 10) methotrexate (MTX) and OC promoter-based toxic gene therapy with either of these single modalities alone. We choose low dose MTX with the intent of determining whether chemosensitization of the osteosarcoma may be possible in combination with gene therapy with an overall reduced toxicity profile and enhanced therapeutic efficacy when compared to a single agent alone. In vitro, the combined treatments of MTX (3 ng/mL) and Ad-OC-TK (20 multiplicity of infection (MOI)/target cell) plus ACV (10 mg/mL) had an additive therapeutic effect over that of either MTX (P <0.05) or Ad-OC-TK plus ACV treatment alone (P <0.05). In vivo, nude mice with subcutaneous tumors of either human osteosarcoma (MG-63) or rat osteosarcoma (ROS) received three intratumoral injections of Ad-OC-TK (5 × 10 8 PFU) plus daily intraperitoneal ACV (40 mg/kg body weight) for 2 weeks in combination with five weekly bolus intraperitoneal MTX (87.5 mg/kg). Osteosarcoma tumor growth was inhibited more efficiently than by either Ad-OC-TK plus ACV (P <0.05) or MTX treatment (P <0.005) alone. At day 45 in the ROS group, 100% of the animals survived when treated with chemogene therapy, whereas 80% survived with gene therapy and no animals survived in the MTX-treated or untreated controls. In summary, we developed a novel therapeutic strategy for the treatment of osteosarcoma employing both chemotherapy and gene therapy. Chemogene therapy could potentially achieve better antitumor effects with reduced toxicity than the conventional chemotherapy or gene therapy protocols alone.

Original languageEnglish (US)
Pages (from-to)359-365
Number of pages7
JournalCancer Gene Therapy
Volume4
Issue number6
StatePublished - 1997
Externally publishedYes

Fingerprint

Osteocalcin
Osteosarcoma
Methotrexate
Genetic Therapy
Suicide
Thymidine Kinase
Acyclovir
Adenoviridae
Therapeutics
Poisons
Therapeutic Uses
Growth
Nude Mice
Neoplasms
Theoretical Models
Body Weight

Keywords

  • Animal model
  • Chemogene therapy
  • Gene therapy
  • Methotrexate
  • Osteocalcin promoter
  • Osteosarcoma
  • Thymidine kinase

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Chemogene therapy : Osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a marine osteosarcoma model. / Cheon, Jun; Ko, Song Chu; Gardner, Thomas; Shirakawa, Toshiro; Gotoh, Akinobu; Kao, Chinghai; Chung, Leland W K.

In: Cancer Gene Therapy, Vol. 4, No. 6, 1997, p. 359-365.

Research output: Contribution to journalArticle

Cheon, Jun ; Ko, Song Chu ; Gardner, Thomas ; Shirakawa, Toshiro ; Gotoh, Akinobu ; Kao, Chinghai ; Chung, Leland W K. / Chemogene therapy : Osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a marine osteosarcoma model. In: Cancer Gene Therapy. 1997 ; Vol. 4, No. 6. pp. 359-365.
@article{b484ab43ca88450e9e81540945976923,
title = "Chemogene therapy: Osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a marine osteosarcoma model",
abstract = "We previously reported that the recombinant adenovirus (Ad) vector containing the thymidine kinase (TK) gene driven by the osteocalcin (OC) promoter (Ad-OC-TK), when delivered concurrently with acyclovir (ACV), is highly selective in blocking the growth of osteosarcoma in experimental models (Cancer Res. 1996;56:4614-4619). To investigate the possible additive effects of the combined treatment of gene therapy and conventional chemotherapy (chemogene therapy), we compared the effect of low dose (IC 10) methotrexate (MTX) and OC promoter-based toxic gene therapy with either of these single modalities alone. We choose low dose MTX with the intent of determining whether chemosensitization of the osteosarcoma may be possible in combination with gene therapy with an overall reduced toxicity profile and enhanced therapeutic efficacy when compared to a single agent alone. In vitro, the combined treatments of MTX (3 ng/mL) and Ad-OC-TK (20 multiplicity of infection (MOI)/target cell) plus ACV (10 mg/mL) had an additive therapeutic effect over that of either MTX (P <0.05) or Ad-OC-TK plus ACV treatment alone (P <0.05). In vivo, nude mice with subcutaneous tumors of either human osteosarcoma (MG-63) or rat osteosarcoma (ROS) received three intratumoral injections of Ad-OC-TK (5 × 10 8 PFU) plus daily intraperitoneal ACV (40 mg/kg body weight) for 2 weeks in combination with five weekly bolus intraperitoneal MTX (87.5 mg/kg). Osteosarcoma tumor growth was inhibited more efficiently than by either Ad-OC-TK plus ACV (P <0.05) or MTX treatment (P <0.005) alone. At day 45 in the ROS group, 100{\%} of the animals survived when treated with chemogene therapy, whereas 80{\%} survived with gene therapy and no animals survived in the MTX-treated or untreated controls. In summary, we developed a novel therapeutic strategy for the treatment of osteosarcoma employing both chemotherapy and gene therapy. Chemogene therapy could potentially achieve better antitumor effects with reduced toxicity than the conventional chemotherapy or gene therapy protocols alone.",
keywords = "Animal model, Chemogene therapy, Gene therapy, Methotrexate, Osteocalcin promoter, Osteosarcoma, Thymidine kinase",
author = "Jun Cheon and Ko, {Song Chu} and Thomas Gardner and Toshiro Shirakawa and Akinobu Gotoh and Chinghai Kao and Chung, {Leland W K}",
year = "1997",
language = "English (US)",
volume = "4",
pages = "359--365",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Chemogene therapy

T2 - Osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a marine osteosarcoma model

AU - Cheon, Jun

AU - Ko, Song Chu

AU - Gardner, Thomas

AU - Shirakawa, Toshiro

AU - Gotoh, Akinobu

AU - Kao, Chinghai

AU - Chung, Leland W K

PY - 1997

Y1 - 1997

N2 - We previously reported that the recombinant adenovirus (Ad) vector containing the thymidine kinase (TK) gene driven by the osteocalcin (OC) promoter (Ad-OC-TK), when delivered concurrently with acyclovir (ACV), is highly selective in blocking the growth of osteosarcoma in experimental models (Cancer Res. 1996;56:4614-4619). To investigate the possible additive effects of the combined treatment of gene therapy and conventional chemotherapy (chemogene therapy), we compared the effect of low dose (IC 10) methotrexate (MTX) and OC promoter-based toxic gene therapy with either of these single modalities alone. We choose low dose MTX with the intent of determining whether chemosensitization of the osteosarcoma may be possible in combination with gene therapy with an overall reduced toxicity profile and enhanced therapeutic efficacy when compared to a single agent alone. In vitro, the combined treatments of MTX (3 ng/mL) and Ad-OC-TK (20 multiplicity of infection (MOI)/target cell) plus ACV (10 mg/mL) had an additive therapeutic effect over that of either MTX (P <0.05) or Ad-OC-TK plus ACV treatment alone (P <0.05). In vivo, nude mice with subcutaneous tumors of either human osteosarcoma (MG-63) or rat osteosarcoma (ROS) received three intratumoral injections of Ad-OC-TK (5 × 10 8 PFU) plus daily intraperitoneal ACV (40 mg/kg body weight) for 2 weeks in combination with five weekly bolus intraperitoneal MTX (87.5 mg/kg). Osteosarcoma tumor growth was inhibited more efficiently than by either Ad-OC-TK plus ACV (P <0.05) or MTX treatment (P <0.005) alone. At day 45 in the ROS group, 100% of the animals survived when treated with chemogene therapy, whereas 80% survived with gene therapy and no animals survived in the MTX-treated or untreated controls. In summary, we developed a novel therapeutic strategy for the treatment of osteosarcoma employing both chemotherapy and gene therapy. Chemogene therapy could potentially achieve better antitumor effects with reduced toxicity than the conventional chemotherapy or gene therapy protocols alone.

AB - We previously reported that the recombinant adenovirus (Ad) vector containing the thymidine kinase (TK) gene driven by the osteocalcin (OC) promoter (Ad-OC-TK), when delivered concurrently with acyclovir (ACV), is highly selective in blocking the growth of osteosarcoma in experimental models (Cancer Res. 1996;56:4614-4619). To investigate the possible additive effects of the combined treatment of gene therapy and conventional chemotherapy (chemogene therapy), we compared the effect of low dose (IC 10) methotrexate (MTX) and OC promoter-based toxic gene therapy with either of these single modalities alone. We choose low dose MTX with the intent of determining whether chemosensitization of the osteosarcoma may be possible in combination with gene therapy with an overall reduced toxicity profile and enhanced therapeutic efficacy when compared to a single agent alone. In vitro, the combined treatments of MTX (3 ng/mL) and Ad-OC-TK (20 multiplicity of infection (MOI)/target cell) plus ACV (10 mg/mL) had an additive therapeutic effect over that of either MTX (P <0.05) or Ad-OC-TK plus ACV treatment alone (P <0.05). In vivo, nude mice with subcutaneous tumors of either human osteosarcoma (MG-63) or rat osteosarcoma (ROS) received three intratumoral injections of Ad-OC-TK (5 × 10 8 PFU) plus daily intraperitoneal ACV (40 mg/kg body weight) for 2 weeks in combination with five weekly bolus intraperitoneal MTX (87.5 mg/kg). Osteosarcoma tumor growth was inhibited more efficiently than by either Ad-OC-TK plus ACV (P <0.05) or MTX treatment (P <0.005) alone. At day 45 in the ROS group, 100% of the animals survived when treated with chemogene therapy, whereas 80% survived with gene therapy and no animals survived in the MTX-treated or untreated controls. In summary, we developed a novel therapeutic strategy for the treatment of osteosarcoma employing both chemotherapy and gene therapy. Chemogene therapy could potentially achieve better antitumor effects with reduced toxicity than the conventional chemotherapy or gene therapy protocols alone.

KW - Animal model

KW - Chemogene therapy

KW - Gene therapy

KW - Methotrexate

KW - Osteocalcin promoter

KW - Osteosarcoma

KW - Thymidine kinase

UR - http://www.scopus.com/inward/record.url?scp=0031267107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031267107&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 359

EP - 365

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 6

ER -